ARCHIVES

The Line Item for Cancer Centers and SPOREs to Remain Flat, Near $598 Million for the 2013 Fiscal Year

This article is from The Cancer Letter archive.

Vol. 38 No. 16 | April 20, 2012

Download PDF Visit The Full Archive

Related Articles

Cell Therapeutics To Appeal FDA Decision on Pixantrone.

September 17, 2010

HHS Inspector General: Busy Signals Greet One In Three Callers To 800-4-CANCER

July 24, 1998

White Heads NIH Legislative Policy Office

March 5, 2010

Novel Antifungal Agent Highly Active Against Esophageal Candidiasis

October 31, 2003

Postponed Surgery For Low-Grade Prostate Cancer Adds No Risk

April 29, 2011

UT System Launches Probe of Submission Of Controversial MD Anderson Grant

June 8, 2012